A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

doi:10.1016/j.mayocp.2021.03.010

Mayo Clinic Proceedings

Volume 96, Issue 5, May 2021, Pages 1250-1261

, , , , , , , , , , , , , , , , , , , …

https://doi.org/10.1016/j.mayocp.2021.03.010 Get rights and content

Abstract

The administration of spike monoclonal antibody treatment to patients with mild to moderate COVID-19 is very challenging. This article summarizes essential components and processes in establishing an effective spike monoclonal antibody infusion program. Rapid identification of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. Our partnerships and collaborations among multiple different specialties and disciplines enabled contributions from personnel with specific expertise in medicine, nursing, pharmacy, infection prevention and control, electronic health record (EHR) informatics, compliance, legal, medical ethics, engineering, administration, and other critical areas. Clear communication and a culture in which all roles are welcomed at the planning and operational tables are critical to the rapid development and refinement needed to adapt and thrive in providing this time-sensitive beneficial therapy. Our partnerships with leaders and providers outside our institutions, including those who care for underserved populations, have promoted equity in the access of monoclonal antibodies in our regions. Strong support from institutional leadership facilitated expedited action when needed, from a physical, personnel, and system infrastructure standpoint. Our ongoing real-time assessment and monitoring of our clinical program allowed us to improve and optimize our processes to ensure that the needs of our patients with COVID-19 in the outpatient setting are met.

Section snippets

A Pandemic Calls for Innovative Clinical Practices

SARS-CoV-2 is a highly infectious viral pathogen, associated with a clinical spectrum ranging from asymptomatic infection to severe and critical COVID-19.⁸ Since it was first reported as an outbreak of a potentially fatal pneumonia in China in December 2019, there have been major efforts in the development of therapeutics for its clinical management. The nucleoside analogue, remdesivir, was the first antiviral drug approved by the US FDA for treatment of severe COVID-19 in the hospital.⁹

Novel Pharmaceutical Therapies Emerge to Prevent Clinical Progression of Disease and Hospitalization

The US FDA has issued separate EUAs to 3 neutralizing monoclonal antibody preparations— bamlanivimab, casirivimab-imdevimab, and bamlanivimab-etesevimab—for early treatment of high-risk patients with mild-to-moderate COVID-19 in the outpatient setting.1, 2, 3 The EUAs are based on preliminary data from early-phase clinical trials that separately compared the monoclonal antibodies with placebo and showed reductions in viral load and, potentially, the need for hospitalizations or emergency

Building the Physical and Electronic Infrastructure for Safe Infusions

Most health care systems, including Mayo Clinic, did not have dedicated infusion facilities serving COVID-19 patients who needed parenteral medications in the outpatient setting. Our existing infusion therapy center (ITC) is generally used by high-risk and immunocompromised patients for infusions of antimicrobials, other monoclonal antibodies, other parenteral medications, and blood products. Because patients who use existing ITC are predisposed to develop severe, critical, and potentially

Identifying Patient Populations at High Risk of Clinical Progression and Hospitalization

Per the FDA EUAs, bamlanivimab, casirivimab-imdevimab, and bamlanivimab-etesevimab may only be given for emergency use to a select group of high-risk individuals.¹⁷ These include patients who are 65 years of age and older; have diabetes; have BMIs greater than or equal to 35; have chronic kidney disease; or those with compromised immune systems, either from disease or from use of immunosuppressive agents. Patients 55 years and older may also be eligible if they have hypertension, cardiovascular

Partnerships With Providers and Health Care Professionals

A multidisciplinary MATRx team was created to tap into the clinical and administrative expertise of multiple providers and health care personnel (Table). Many members are also part of the CFCT, which ensured coordination between monitoring and treatment groups.¹⁴^,¹⁵ The MATRx clinical team developed the process of drug allocation, based on guidance from the FDA and our states’ Departments of Health and Human Services, with input from medical ethics and legal colleagues to ensure a fair and

Optimizing Processes and Measuring Outcomes

The interplay among various components of the monoclonal antibody allocation and administration workflow is depicted in Figures 1 and 2. Adjustments to this workflow were made across our infusion sites, based on federal, state, and local regulations. A monoclonal antibody treatment registry of all screened and infused patients with COVID-19 serves our aim to examine and refine our clinical program continually, improve the quality of care we provide, and assess our outcomes. Continuous quality

Conclusion

This article summarizes the essential components and processes of an effective spike monoclonal antibody infusion program for patients with mild-to-moderate COVID-19 in the outpatient setting. Rapid designation of a dedicated physical infrastructure was essential to circumvent the logistical challenges of caring for infectious patients while maintaining compliance with regulations and ensuring the safety of our personnel and other patients. This was made possible by the willingness of other

Acknowledgments

The authors would like to express appreciation to all the patients and their legally authorized representatives for trusting us with their medical care; our nurses and providers who contacted our patients and provided education; our desk operations who assisted in the care of our patients; and our personnel who transported medications to our off-site infusion units and safely transported our mobile infusion teams to nursing homes and long-term care facilities. The authors also thank information

References (17)

R.R. Razonable et al.
A collaborative multidisciplinary approach to the management of coronavirus disease 2019 in the hospital setting
Mayo Clin Proc
(2020)
R.R. Razonable et al.
Clinical guidance and the delivery of care for patients with coronavirus disease 2019
Mayo Clin Proc
(2020)
S.J. Crane et al.
Telemedicine consultations and follow-up of patients with COVID-19
Mayo Clin Proc
(2020)
R. Ganesh et al.
Managing patients in the Covid-19 pandemic: a virtual multidisciplinary approach
Mayo Clin Proc Innov Qual Outcomes
(2021)
D.M. Weinreich et al.
REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19
N Engl J Med
(2021)
P. Chen et al.
SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19
N Engl J Med
(2021)
R.L. Gottlieb et al.
Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial
JAMA
(2021)
F.P. Polack et al.
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
N Engl J Med
(2020)

There are more references available in the full text version of this article.

Cited by (35)

Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019
2022, Mayo Clinic Proceedings
Citation Excerpt :
On November 7, 2020, Mayo Clinic established its Monoclonal Antibody Treatment (MATRx) program to administer anti-spike monoclonal antibodies to high-risk patients with mild to moderate COVID-19. The MATRx program, protocols, and procedures have been described previously.17 For this study, only patients treated in Minnesota and Wisconsin were included.
To describe and compare the clinical outcomes of bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab treatment of mild to moderate coronavirus disease 2019 (COVID-19) during the severe acute respiratory coronavirus 2 (SARS-CoV-2) B.1.617.2 Delta surge.
This is a retrospective study of high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 between August 1, 2021, and December 1, 2021. Rates of severe disease, hospitalization, intensive care unit admission, and death were assessed.
Among 10,775 high-risk patients who received bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab for mild to moderate COVID-19 during the Delta surge, 287 patients (2.7%) developed severe disease that led to hospitalization, oxygen supplementation, or death within 30 days after treatment. The rates of severe disease were low among patients treated with bamlanivimab-etesevimab (1.2%), casirivimab-imdevimab (2.9%), and sotrovimab (1.6%; P<.01). The higher rate of severe outcomes among patients treated with casirivimab-imdevimab may be related to a significantly lower COVID-19 vaccination rate in that cohort. Intensive care unit admission was comparable among patients treated bamlanivimab-etesevimab, casirivimab-imdevimab, or sotrovimab (1.0%, 1.0%, and 0.4%, respectively).
This real-world study of a large cohort of high-risk patients shows low rates of severe disease, hospitalization, intensive care unit admission, and mortality after treatment with bamlanivimab-etesevimab, casirivimab-imdevimab, and sotrovimab for mild to moderate COVID-19 during the SARS-CoV-2 Delta surge.
Rates of Severe Outcomes After Bamlanivimab-Etesevimab and Casirivimab-Imdevimab Treatment of High-Risk Patients With Mild to Moderate Coronavirus Disease 2019
2022, Mayo Clinic Proceedings
Citation Excerpt :
On November 7, 2020, Mayo Clinic established its Monoclonal Antibody Treatment (MATRx) program to administer antispike monoclonal antibodies to patients at high risk of severe disease in an attempt to mitigate the risk of disease progression and hospitalization. The MATRx program, protocols, and procedures have been described previously.9 For this study, only patients treated in Minnesota and Wisconsin were included.
Bamlanivimab-etesevimab and casirivimab-imdevimab are authorized by the US Food and Drug Administration for emergency treatment of mild to moderate coronavirus disease 2019 (COVID-19) in high-risk persons. There has been no study comparing their clinical efficacy. In this retrospective study of 681 patients with mild to moderate COVID-19 during a period dominated by severe acute respiratory syndrome coronavirus 2 wild-type and alpha variants, 25 patients (3.7%) had progression to a severe outcome requiring hospitalization and oxygen supplementation within 30 days after monoclonal antibody infusion. Severe outcome was significantly higher among the 181 patients who were treated with casirivimab-imdevimab when compared with the 500 patients who received bamlanivimab-etesevimab (21 [6.6%] vs 13 [2.6%]; P=.01). Patients treated with casirivimab-imdevimab had higher odds of severe outcomes compared with those who received bamlanivimab-etesevimab (odds ratio, 2.67; 95% CI, 1.17 to 6.06). The demographic and clinical characteristics, and the time to monoclonal antibody infusion, of the 2 treatment cohorts were not significantly different. The reason behind this significant difference in the clinical outcomes is unclear, but our observations emphasize potential efficacy differences among antispike monoclonal antibodies against COVID-19. Further clinical studies using larger cohorts of patients are needed to confirm or refute these observations.
The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: A retro-prospective comparative study in India
2022, Clinical Epidemiology and Global Health
Citation Excerpt :
In this context, the vaccine might have generated a synergistic impact on the benefits of the antibody cocktail. We know that the monoclonal antibody is warranted for highly risk communities, so it is essential to consider co-morbidities in our discussion.25 There was no difference in COVID19 patients between co-existing multiple chronic conditions and both mechanical ventilation and high flow oxygen requirement.
Monoclonal antibodies have gained attention in developing countries owing to its benefits portrayed by few clinical trials. However, no studies until now have been undergone in India.
A retro-prospective comparative observational study was conducted in symptomatic COVID19 patients to evaluate the impact of Casirivimab and Imdevimab antibody cocktail in the high-risk population. Through an extensive data retrieval for 6 months, 152 samples were documented and sorted into test (Casirivimab and Imdevimab treated patients, n = 79) and control (Non- Casirivimab and Imdevimab treated individuals, n = 73) subsets. The research had two phases; first, estimation of mechanical ventilation and high flow oxygen requirement and mortality in samples amidst the treatment, and second was the post COVID19 patients' feedback through validated (Cronbach's alpha coefficient = 0.7) questionnaire that evaluated their health and vaccination status, and treatment satisfaction.
We noticed lesser requisite for mechanical ventilation (6.3%; p < 0.001), high flow oxygen (5.1%; p < 0.001) and no death during Casirivimab and Imdevimab therapy. Meanwhile, non-vaccinated test groups were not on mechanical ventilation and those fully immunized seldom entailed high flow oxygen (test, 6.3%; control, 41.9%, p < 0.01). On evaluating the post COVID19 status of each patient in the study, 90.1% of the test samples were healthy and 97.2% were satisfied with the treatment than those in control group.
Casirivimab and Imdevimab regimen was clinically beneficial for high risk COVID19 patients than those treated without the antibody cocktail.
Effectiveness of Monoclonal Antibodies in Preventing Severe COVID-19 With Emergence of the Delta Variant
2022, Mayo Clinic Proceedings
Anti-spike monoclonal antibodies have proven invaluable in preventing severe outcomes from COVID-19, including hospitalization and death. The rise of the SARS-CoV-2 delta variant begs the question of whether monoclonal antibodies maintain similar efficacy now as they had when the alpha and beta variants predominated, when they were first assessed and approved. We used a retrospective cohort to compare rates of severe outcomes in an epoch in which alpha and beta were predominant compared with delta. A total of 5356 patients were infused during the alpha/beta variant–predominant (n=4874) and delta variant–predominant (n=482) era. Overall, odds of severe infection were 3.0% of patients in the alpha/beta-predominant era compared with 4.9% in the delta-predominant cohort. The unadjusted odds ratio (OR) was higher for severe disease in the delta era (OR, 1.67; 95% CI, 0.96 to 2.89), particularly when adjusted for Charlson Comorbidity Index (adjusted OR, 2.04; 95% CI, 1.30 to 3.08). The higher odds of severe infection could be due to a more virulent delta variant, although the possibility of decreased anti-spike monoclonal antibody effectiveness in the clinical setting cannot be excluded. Research into the most effective strategies for using and improving anti-spike monoclonals for the treatment of emerging variants is warranted.
Health System Success in Delivering Bamlanivimab Within Post-acute and Long-Term Care Facilities
2022, Journal of the American Medical Directors Association
Citation Excerpt :
This agile response resulted in medication access for PALTC residents in the critical weeks before infusion centers and teams were created. Some health systems created dedicated infusion centers and/or mobile infusion teams.11 It is not yet published how successful this approach was at reaching PALTC residents.
Post-acute and long-term care (PALTC) residents are disproportionately affected by coronavirus 2019 (COVID-19). We describe a health system approach that incorporated PALTC stakeholders to treat residents effectively and efficiently with monoclonal antibodies during the pandemic.
Retrospective observational.
Integrated health system headquartered in Sioux Falls, South Dakota, with urban hub and surrounding rural communities. Patients of the health system include PALTC and assisted living (AL) residents of facilities.
Monoclonal Data Registry captured time to infusion after a positive COVID-19 test, residency (independent or PALTC), and site of infusion (PALTC, hospital outpatient, infusion center). AL residents are included in PALTC data. Registry limited to patients living in SD. Communication and operational resources were tailored to support PALTC infusions. The monoclonal antibody therapy administered to PALTC residents during the first 6 weeks after emergency use authorization (EUA) of monoclonal antibodies was bamlanivimab. The EUA for bamlanivimab was revoked due to lack of effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants on April 16, 2021.
The results are analyzed for the 6 weeks after bamlanivimab EUA. In PALTC, there was a median of 3 days between positive test and infusion. The total number of monoclonal antibody infusions captured in the registry during this time was 87 PALTC on-site infusions.
A collaborative approach between health system executives and PALTC experts quickly enabled access to potentially life-saving therapy to a vulnerable population. PALTC settings should be routinely included in health system investment and planning to improve the capacity of the system to achieve optimal outcomes, prevent unnecessary mortality, and preserve health care resources.
Clinical Prioritization of Antispike Monoclonal Antibody Treatment of Mild to Moderate COVID-19
2022, Mayo Clinic Proceedings

View all citing articles on Scopus

: Grant Support: Dr Razonable has received a Mayo Clinic Research award.

: Potential Competing Interests: The authors report no competing interests.

View full text

Special articleA Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model

Abstract

Section snippets

A Pandemic Calls for Innovative Clinical Practices

Novel Pharmaceutical Therapies Emerge to Prevent Clinical Progression of Disease and Hospitalization

Building the Physical and Electronic Infrastructure for Safe Infusions

Identifying Patient Populations at High Risk of Clinical Progression and Hospitalization

Partnerships With Providers and Health Care Professionals

Optimizing Processes and Measuring Outcomes

Conclusion

Acknowledgments

Mayo Clin Proc

Mayo Clin Proc

Mayo Clin Proc

Mayo Clin Proc Innov Qual Outcomes

REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19

N Engl J Med

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

N Engl J Med

Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial

JAMA

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

N Engl J Med

Special article
A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model